Market Place
Sourcing Support
Aro Biotherapeutics Opens Phase 1b Trial for ABX1100 in LOPD
29 Oct 2024 //
BUSINESSWIRE
Aro Biotherapeutics to Present Updates on ABX1100
06 Feb 2024 //
BUSINESSWIRE
Aro Biotherapeutics Secures $41.5M Series B Financing
28 Nov 2023 //
BUSINESSWIRE
Aro Biotherapeutics Announces Start of First in Human Study with ABX1100
25 Oct 2023 //
BUSINESSWIRE
US FDA grants Rare Paediatric Drug Designation to Aro Bio’s ABX1100
17 Sep 2022 //
PHARMABIZ
Aro Receives FDA Rare Pediatric Drug Designation for ABX1100
15 Sep 2022 //
BUSINESSWIRE
Aro Biotherapeutics Receives FDA Orphan Drug Designation for ABX1100
10 Aug 2022 //
BUSINESS WIRE
Aro Biotherapeutics to Present New Preclinical Data on Centyrin-siRNA Conjugates
11 May 2022 //
BUSINESSWIRE
Aro Bio to Highlight Potential of Centyrin Oligonucleotide Conjugates
30 Mar 2022 //
BUSINESSWIRE
Aro Biotherapeutics Appoints Mittie Doyle, MD, FACR as Chief Medical Officer
07 Oct 2021 //
BUSINESSWIRE
Aro Biotherapeutics Expands Leadership Team and Plans
04 Aug 2021 //
BUSINESSWIRE
Aro Expands Leadership Team with Addition of Proven Scientific Executives
23 Feb 2021 //
BUSINATSSWIRE
Aro Announces $88 Million Series A Financing to Advance Development of Centyrin
04 Jan 2021 //
BUSINESSWIRE
Aro Collaboration with Ionis Advances with Option Exercise
06 Oct 2020 //
BUSINESSWIRE
Boehringer Ingelheim Partners with Enleofen
09 Jan 2020 //
BUSINESS WIRE
Aro Biotherapeutics to Present Data on Lead Program, ABX900, at AACR
02 Apr 2019 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.